Endometrial carcinoma
MONDO:0002447A malignant tumor arising from the epithelium that lines the cavity of the uterine body. The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases. Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma. Uterine bleeding is an initial clinical sign. The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.
Also known as: endometrial cancer, carcinoma of endometrium, carcinoma of the endometrium, carcinoma, endometrial, malignant, endometrial carcinoma, endometrial carcinoma (disease), endometrium carcinoma
3135 clinical trials for this condition and its sub-types, 209 tagged with Endometrial carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrial carcinoma
-
Endometrium adenocarcinoma 30 trials · 119 incl. sub-types
9 sub-types
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Endometrial mixed adenocarcinoma 10 trials
- Endometrial mucinous adenocarcinoma 2 trials
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells 0 trials
- Mucin-rich endometrial endometrioid adenocarcinoma 0 trials
- Oxyphilic endometrial endometrioid adenocarcinoma 0 trials
- Secretory uterine corpus endometrioid adenocarcinoma 0 trials
- Villoglandular endometrial endometrioid adenocarcinoma 0 trials
-
Endometrial squamous cell carcinoma 0 trials · 2 incl. sub-types
1 sub-type
- Endometrial adenosquamous carcinoma 2 trials
-
Endometrium carcinoma in situ 1 trial
-
Endometrial small cell carcinoma 0 trials
-
Uterine corpus endometrial carcinoma 0 trials
Most studied deeper sub-types
-
Can an immunotherapy drug replace surgery for some endometrial cancers?
Cure Not yet recruitingThis phase 2 trial is testing whether the immunotherapy drug sintilimab can eliminate early-stage (I-II) MSI-H/dMMR endometrial cancer without the need for surgery. About 48 participants will receive sintilimab alone every three weeks. The goal is to see if the drug can produce a…
Phase 2 • Sponsor: Wang Jianliu • Aim: Cure
Last updated Jul 30, 2026 00:00 UTC
-
New drug combo aims to stall endometrial cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a natural compound boost chemotherapy against endometrial cancer?
Disease control Not yet recruitingThis trial is testing whether adding elemene liposomes—a compound derived from a traditional Chinese medicinal plant—to standard chemotherapy (carboplatin and paclitaxel) can help people with advanced or recurrent endometrial cancer. Participants will receive either the combinati…
Phase 2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
Disease control Not yet recruitingThis trial tests whether an online, personalized lifestyle program can help rural postmenopausal breast and endometrial cancer survivors lose weight and improve their health. Participants follow a tailored diet and aerobic exercise plan, with mobile health tools to track progress…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Experimental drug TJ037130 takes aim at advanced solid tumors
Disease control Not yet recruitingThis phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…
Phase 1 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Radiotherapy revolution: could 5 sessions replace 25 for endometrial cancer?
Disease control Not yet recruitingThis trial explores whether a new type of radiotherapy called CT online-adaptive radiotherapy can safely deliver treatment for endometrial cancer in just 5 sessions over a week and a half, instead of the usual 25 sessions over 5 weeks. The study includes 30 adults who have had su…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
Disease control Not yet recruitingThis early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…
Phase 1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tame advanced uterine cancer
Disease control Not yet recruitingThis study tests the safety of the immunotherapy drug dostarlimab when given together with standard chemotherapy (carboplatin and paclitaxel) as a first treatment for adults in India with advanced or recurrent endometrial cancer. Participants receive the drug combination initiall…
Phase 4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hormone blocker plus targeted drug shows promise against tough uterine cancer
Disease control Not yet recruitingThis phase II trial tests whether combining elacestrant, a drug that lowers estrogen, with everolimus, which stops cancer cells from growing and cuts their blood supply, can control advanced or recurrent ER+ endometrial cancer. About 50 adults whose cancer has returned or spread …
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill shows promise for Hard-to-Treat uterine cancer
Disease control Not yet recruitingThis phase 2 trial is testing a daily pill called Inavolisib in about 48 people with advanced endometrial cancer that has a specific genetic change (PIK3CA mutation). The drug targets that mutation to try to shrink tumors or stop them from growing. Researchers will measure how ma…
Phase 2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Minimally invasive surgery may offer safer option for early endometrial cancer
Disease control Not yet recruitingThis study compares two surgical approaches for early-stage endometrial cancer: laparoscopic staging (minimally invasive) and open staging laparotomy (traditional open surgery). Researchers will enroll 30 patients to see if laparoscopy is as safe and effective as open surgery, wi…
Sponsor: Ain Shams Maternity Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a drug combo replace the knife for some endometrial cancers?
Disease control Not yet recruitingThis study tests two immunotherapy drugs (iparomlimab and tuvonralimab) in 30 women with a specific type of endometrial cancer that is mismatch repair-deficient. The goal is to see if the treatment can make the cancer disappear or shrink enough to avoid surgery. Participants must…
Phase 2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New targeted drug shows promise for Hard-to-Treat gynecologic cancers
Disease control Not yet recruitingThis study tests a new drug called BRY812 in people with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The goal is to see if the drug can shrink tumors and how safe it is. About 56 participants will receive the drug, and researc…
Phase 2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug cocktail aims to fight advanced uterine cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the drug EG-007 to a standard combination of lenvatinib and pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 participants will be randomly assigned to receive eithe…
Phase 3 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for advanced endometrial cancer: Triple-Drug combo enters safety testing
Disease control Not yet recruitingThis phase 2 trial tests whether adding a repurposed drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. The study will enroll 28 adults whose cancer has progressed after platinum chemoth…
Phase 2 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
AI body scans could make chemo safer for women with ovarian and endometrial cancer
Disease control Not yet recruitingThis study tests whether using an AI tool to analyze a patient's body composition from a CT scan can help doctors personalize chemotherapy dosing. The goal is to reduce severe side effects like low white blood cell counts in women with endometrial or ovarian cancer. About 294 par…
Sponsor: National Cheng-Kung University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Aspirin may fight Cancer-Causing inflammation in the womb
Prevention Not yet recruitingThis study tests whether taking low-dose aspirin can lower inflammation in the womb lining and help prevent endometrial cancer. It involves 25 postmenopausal women who have non-atrophic endometrial changes and pain. Participants will be randomly assigned to take aspirin or not, a…
Phase 4 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Can a Plant-Based diet improve life for women with metastatic cancer?
Symptom relief Not yet recruitingThis study tests whether a whole food, plant-based diet combined with behavioral education can improve quality of life and diet adherence in 60 women with metastatic breast or endometrial cancer. Participants are randomly assigned to either the plant-based diet with support or a …
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Scientists hunt for biomarkers to personalize endometrial cancer immunotherapy
Knowledge-focused Not yet recruitingThis study will analyze tumor samples from 50 women with advanced or recurrent endometrial cancer to find biological markers that predict whether immunotherapy will work. Researchers will examine the tumor's DNA, epigenetics, and surrounding environment. The goal is to better und…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New study explores combining cancer and blood vessel surgery for advanced gynecologic tumors
Knowledge-focused Not yet recruitingThis study looks at how well patients do after surgery that removes both advanced gynecologic cancers and the major blood vessels they have grown into. Researchers will track 130 participants for up to 5 years to see survival rates and how long it takes for the cancer to return. …
Sponsor: National Cancer Institute, Naples • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC